U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07777614) titled 'OPTIMISE Lung SABR' on May 28.
Brief Summary: This study is a phase II multi-centre, randomised study independently evaluating five fraction Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) and three fraction IG-SABR for patients with a peripherally located T1-T2 and selected T3 and T4 lung tumours, or a peripherally located single pulmonary oligometastatic lesion.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
RADIATION: Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment
IG-SABR using a total of 5 fractions (12 Gy per fractio...